Progyny, Inc (NASDAQ: PGNY) shares have weakened more than 20% since November 05, even though the company reported strong third-quarter results.
Management expects a further business acceleration
Progyny is a company that specializes in fertility and family building benefits solutions for employers in the United States by the combination of clinical and emotional support.
Progyny reported strong third-quarter results in November; total revenue has increased by 23.6% Y/Y to $122.28 million, slightly below expectations, while the GAAP earnings per share were $0.17 (beats by $0.12).
Fertility benefit services revenue has increased 17% compared to the third quarter last year to $73.1 million, while Pharmacy revenue increased 43% and reached $37 million.
Gross profit for the third quarter was $28.5 million, up 37% from the third quarter of 2020, and it is important to say that the gross margin has increased by 220 basis points from the prior-year period.
Strong results during the third quarter were primarily driven by the increase in the number of clients and covered lives. During the third-quarter earnings report call, the company’s management announced that the full year 2021 revenue growth should be between 47% and 49%.
The company’s management also reported that it expects a further business acceleration in the upcoming quarters. Pete Anevski, Progyny’s President and Chief Operating Officer, added:
Given the momentum in new sales activity, as well as our near 100% client retention rate, we expect that revenue will grow by approximately 50% in 2022, which is comparable to the rate of growth that we expect to achieve for the full 2021 fiscal year. The company anticipates having 265 clients representing an estimated 4 million covered lives by the end of the second quarter of 2022.
Progyny ended the third quarter with 188 clients (each with at least 1000 covered lives), reflecting a growth of approximately 39% compared with the first nine months of 2020.
Progyny is expanding its market share, but with a $4.65 billion market capitalization, shares of this company are not cheap.
Progyny trades at more than a hundred times TTM EBITDA, the book value per share is $2.9, and there are better investment opportunities at the moment.
$60 represents resistance level
Progyny’s stock is currently down more than 20% after reaching its record high of $68,32 on November 05.
Data source: tradingview.com
The strong support level stands at $45, and if the price falls below this level, it would be a strong “sell” signal.
On the other side, if the price jumps above $60 resistance, it would signal trading shares, and the next target could be at $65 or even above.
Summary
Progyny reported strong third-quarter results in November, and the company’s management expects a further business acceleration in the upcoming quarters. Progyny is expanding its market share, but with a $4.65 billion market capitalization, shares of this company are not cheap.
The post Is Progyny a good buy opportunity at the current share price? appeared first on Invezz.
